FY2027 EPS Estimate for Zealand Pharma A/S Raised by Analyst

Key Points

• William Blair increased the FY2027 EPS estimate for Zealand Pharma A/S from $7.00 to $7.31, while the current consensus estimate for earnings is a loss of ($2.19) per share.
• Several brokerages, including Barclays and BNP Paribas, upgraded Zealand Pharma's rating to "strong-buy," contributing to a consensus rating of "Strong Buy" across analysts.
• Despite a recent share price increase, Zealand Pharma A/S reported a significant earnings miss with EPS of $16.06 for the last quarter, falling short of the consensus estimate of $16.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) - Equities researchers at William Blair upped their FY2027 earnings per share estimates for Zealand Pharma A/S in a note issued to investors on Thursday, August 14th. William Blair analyst A. Hsieh now expects that the company will post earnings per share of $7.31 for the year, up from their prior forecast of $7.00. The consensus estimate for Zealand Pharma A/S's current full-year earnings is ($2.19) per share.

ZLDPF has been the topic of several other research reports. Wells Fargo & Company upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Thursday, July 24th. BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Zacks Research downgraded Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a report on Friday, August 15th. Finally, Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. Five research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy".

Zealand Pharma A/S Price Performance

Shares of ZLDPF remained flat at $61.00 during trading hours on Friday. The stock had a trading volume of 159 shares, compared to its average volume of 563. The firm has a market cap of $4.33 billion, a price-to-earnings ratio of 4.28 and a beta of 0.71. The company's 50-day moving average is $57.26 and its 200 day moving average is $70.28. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03. Zealand Pharma A/S has a 1 year low of $49.98 and a 1 year high of $136.76.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported $16.06 earnings per share for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). The firm had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $9.18 billion. Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 82.30%.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.